Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Takashi Kasai, Takahiko Tokuda, Noriko Ishigami, Hiroshi Sasayama, Penelope Foulds, Douglas J. Mitchell, David M A Mann, David Allsop, Masanori Nakagawa

    Research output: Contribution to journalArticlepeer-review


    There is mounting pathological, biochemical and genetic evidence that the metabolism and aggregation of the 43-kDa transactive response (TAR)-DNA-binding protein (TDP-43) play a crucial role in the pathogenesis of sporadic and some forms of familial amyotrophic lateral sclerosis (ALS). Recently, it was reported using an ELISA system that elevated levels of TDP-43 were detected in plasma samples from patients with Alzheimer's disease and frontotemporal dementia, compared to healthy controls. To determine whether quantification of TDP-43 in cerebrospinal fluid (CSF) is potentially informative in the diagnosis of ALS, we measured the concentration, by a similar ELISA method, of TDP-43 in CSF from 30 patients with ALS (diagnosed according to the revised El Escorial criteria) and 29 age-matched control patients without any neurodegenerative disease. We found that, as a group, the ALS patients had significantly higher levels of TDP-43 in their CSF than the age-matched controls (6.92 ± 3.71 ng/ml in ALS versus 5.31±9 ng/ml in controls, p <0.05), with levels of TDP-43 in CSF elevated beyond 95% upper confidence level for the control group in six (20%) of the patients with sporadic ALS. All the six patients with higher levels of CSF TDP-43 were examined within 10 months of the onset of illness. The patients examined within 10 months of onset showed significantly higher levels of CSF TDP-43 (8.24 ± 4.72 ng/ml) than those examined after 11 months or more of onset (5.41 ± 0.66 ng/ml, p <0.05). These results suggest that the levels of TDP-43 in CSF may increase in the early stage of ALS. We also confirmed the existence of the TDP-43 protein in CSF from some patients with ALS, and a control subject, by western blotting of proteins immunocaptured from the CSF samples. Raised TDP-43 levels in the CSF may preempt the formation of TDP-43 pathology in the central nervous system, or correlate with early-stage TDP-43 pathology, and accordingly be a biomarker for the early stage of ALS. © Springer-Verlag 2008.
    Original languageEnglish
    Pages (from-to)55-62
    Number of pages7
    JournalActa Neuropathologica
    Issue number1
    Publication statusPublished - 2009


    • Amyotrophic lateral sclerosis
    • Biomarker
    • Cerebrospinal fluid
    • ELISA
    • TDP-43


    Dive into the research topics of 'Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

    Cite this